Sort   by:  
 Page size 
ProteomicsDynamic global acetylation remodeling during the yeast heat shock response
All organisms experience stress and must rapidly respond to changing conditions. Thus, cells have evolved sophisticated rapid-response mechanisms such as post-translational protein modification to rapidly and reversibly modulate protein activity. One such post-translational modification is reversibl...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2025-05-03 | PXD063569 | Pride
Acetylome Heat shock Tmt Stress Yeast 
TranscriptomicsComparison of the transcriptional response to ethanol in laboratory and wild yeast strains
An S288c-derived lab strain of Saccharomyces cerevisiae has lower ethanol resistance than either the vineyard strain M22 or the oak strain YPS163. We performed a 60 minute time-course experiment in the presence of 5% ethanol and compared the transcriptional response to ethanol between strains. We ...
ORGANISM(S): Saccharomyces cerevisiae 
2010-12-17 | E-GEOD-22904 | biostudies-arrayexpress
ProteomicsQuantitative proteomic analysis of heat shock response using tandem mass tags
Analysis of precision of TMT quantitation at the peptide level using multinotch MS3
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2020-02-17 | PXD014552 | Pride
Lc-ms Tmt 
ProteomicsQuantitative proteomic analysis of heat shock response using tandem mass tags
Analysis of precision of TMT quantitation at the peptide level using multinotch MS3
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2020-02-18 | PXD012973 | Pride
Lc-ms Tmt 
TranscriptomicseQTL Mapping of the Yeast Ethanol Response
In a previous study, we identified extensive natural variation in the response to acute ethanol treatment in three yeast strains: a lab strain derived from the commonly used S288c (DBY8268), vineyard isolate M22, and oak soil strain YPS163. Many expression differences persisted across several module...
ORGANISM(S): Saccharomyces cerevisiae 
2014-10-02 | E-GEOD-54196 | biostudies-arrayexpress
UnknownPhase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Not available
S-EPMC4878037 | biostudies-literature
UnknownCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Not available
S-EPMC4226803 | biostudies-literature
UnknownHeterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
Not available
S-EPMC5992134 | biostudies-literature
UnknownDominant negative variants in IKZF2 cause ICHAD syndrome, a new disorder characterised by immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay.
Not available
S-EPMC11206234 | biostudies-literature
UnknownComplement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups.
Not available
S-EPMC10084477 | biostudies-literature
Sort   by:  
 Page size